Join the club for FREE to access the whole archive and other member benefits.

Insilico Medicine series D funding to grow its pipeline and create an AI-driven robotic drug discovery laboratory


Key points from article :

Insilico Medicine has completed a $60 million Series D financing from a syndicate of global investors.

Capital raised will fuel the growth of its advancing pipeline, including its lead program which is currently in a Phase I study.

Proceeds will also fund a fully automated, AI-driven robotic drug discovery laboratory, and fully robotic biological data factory to complement the company’s vast curated data assets.

“It is a testament to the strength of our end-to-end AI platform, which has been validated by many partners,” said Alex Zhavoronkov, Founder and CEO.

Seven programs in its internal pipeline have progressed to the IND-enabling stage.

"We plan to continue expanding the breadth of the pipeline and enhance our AI and robotics capabilities globally," explained Feng Ren,  Insilico’s CSO.

Since the launch of its PandaOmics and Chemistry42 in late 2020, nine out of the top 20 pharmaceutical companies, as measured by 2020 revenue, have licensed Insilico’s AI platforms.

Big data combined with laboratory automation - the pace of drug discovery is about to take off!

Mentioned in this article:

Click on resource name for more details.

Alex Zhavoronkov

CEO of InSilico Medicine & Deep Longevity. CSO of Biogerontology Research Foundation.

Insilico Medicine

Biotechnology company that uses artificial intelligence to develop new drugs and for aging research

Ren Feng

Insilico Medicine's chief scientific officer (CSO) and Head of R&D